Kratom & the FDA: Where Regulation Stands in 2026

The FDA's position on kratom in 2026 is the most nuanced it has been since the agency first publicly addressed the botanical. The landmark FDA-funded clinical trial published in January 2026 found dried kratom leaf powder safe and well-tolerated. The DEA's July 2026 notice of intent to schedule concentrated 7-OH products — at the FDA's recommendation — explicitly distinguished natural kratom leaf from synthetic 7-OH products for the first time. And the growing number of KCPA states demonstrates a regulatory alternative to prohibition that the FDA has not publicly endorsed but has not opposed either.

FDA's Current Stance

The FDA maintains that kratom has no approved medical uses and continues to warn consumers about safety risks. The agency has not changed its fundamental position that kratom products should not be marketed with health claims. However, the agency's July 2025 recommendation to the DEA specifically targeted concentrated 7-OH products — tablets, gummies, shots, and strips with elevated 7-OH levels — and explicitly stated it was "not focused on natural kratom leaf products." This distinction, while narrow, is significant: it is the first time the FDA has formally separated natural kratom leaf from concentrated alkaloid products in a regulatory action.

The January 2026 Clinical Trial

The largest controlled kratom study ever conducted, funded by the FDA and published in January 2026, enrolled 116 healthy volunteers in a 47-day trial. Participants received dried kratom leaf powder in controlled settings with medical monitoring. The study found no serious adverse events, no evidence of meaningful abuse potential (euphoric mood was reported in only 3 participants across all active dose groups, comparable to placebo), and minimal withdrawal-related events during the follow-up period. While a single clinical trial does not settle the safety question definitively, this study provides the strongest evidence to date that kratom leaf powder, when used as studied, does not present the acute safety risks that the FDA's previous warnings emphasized.

The DEA's July 2026 Action

On July 1, 2026, the DEA signed a notice of intent to temporarily place synthetic and concentrated 7-hydroxymitragynine above a specified threshold into Schedule I of the Controlled Substances Act. The temporary scheduling order can take effect after a 30-day public comment period — making early August 2026 the earliest effective date. The order would last two years, extendable by one year, while the DEA pursues permanent scheduling through standard rulemaking.

Critically, this action targets concentrated 7-OH products — not natural kratom leaf. The DEA and HHS press releases explicitly stated that the action "is not intended to regulate natural leaf kratom that does not contain enhanced levels of 7-OH." For consumers of standard kratom powder, capsules, and natural leaf extract, this action changes nothing about the legal status of their products at the federal level. For consumers of concentrated 7-OH products (tablets, gummies, shots, strips), these products will become Schedule I controlled substances once the order takes effect.

State-Level Developments

Tennessee became the eighth state to ban kratom when Governor Bill Lee signed HB1649/SB1656 on May 7, 2026, effective July 1, 2026. Rhode Island reversed its ban effective April 1, 2026, adopting a KCPA framework — the first state to move from prohibition to regulated-legal status. Active ban bills are pending in Georgia, South Carolina, Washington, Michigan, and several other states. The KCPA continues to expand, with New York adopting a framework in 2026 and multiple states considering KCPA-style legislation as an alternative to prohibition.

What This Means for Consumers

The regulatory landscape is bifurcating. Natural kratom leaf is moving toward regulated-legal status in most states through KCPA frameworks, with federal enforcement focused on marketing claims rather than the product itself. Concentrated 7-OH products are moving toward federal prohibition through DEA scheduling. Consumers of standard kratom leaf powder, capsules, and natural extracts are in a more secure legal position than at any point in the past decade — the regulatory pressure that threatened natural kratom has been redirected toward the concentrated 7-OH products that represent a genuinely different risk category.

What the Clinical Trial Changes

The January 2026 FDA-funded clinical trial is significant not just for its findings but for its existence. The fact that the FDA funded a controlled kratom safety study indicates a shift from the agency's previous position of opposing kratom primarily through warning letters and import alerts toward an evidence-based assessment of the botanical's safety profile. The trial's finding of no serious adverse events and no meaningful abuse potential provides data-driven support for regulatory approaches (like the KCPA) that regulate quality rather than prohibit the product entirely. Anti-kratom regulatory efforts that previously cited a lack of clinical safety data now face a published, peer-reviewed, FDA-funded study that contradicts their core safety arguments.

The trial also establishes a baseline methodology for future kratom research. Its dosing protocols, monitoring procedures, and assessment tools provide a template that other researchers can replicate and extend — studying different populations, longer durations, or specific safety questions that the initial trial did not address. The coming years are likely to see additional clinical research building on this foundation, which will further inform regulatory decisions at both federal and state levels.

Industry Self-Regulation and the AKA

The American Kratom Association has positioned itself as the industry's primary self-regulatory body, developing the GMP Standards Program, advocating for KCPA legislation in state capitals, and engaging with federal agencies on regulatory policy. The AKA's approach — promoting quality standards and consumer protection rather than opposing all regulation — has gained traction with state legislators who see regulation as preferable to both prohibition and unregulated market chaos. The growing number of KCPA states validates this strategy and provides a legislative model that additional states can adopt with minimal modification.

However, the AKA is an industry advocacy organization, not a government regulatory body. Its GMP program is voluntary, its enforcement authority is limited to removing non-compliant vendors from its qualified list, and its policy positions naturally favor the interests of its member vendors. Consumers should view AKA GMP qualification as a meaningful but not definitive quality indicator — one data point among several (lab testing, community reputation, business longevity) that inform purchasing decisions.

Congressional Activity

Congress has engaged with kratom policy primarily through oversight rather than legislation. Congressional letters to the FDA and DEA — including bipartisan letters signed by members of both the House and Senate — have urged federal agencies to consider the regulatory distinction between natural kratom leaf and concentrated 7-OH products, and to avoid scheduling actions that would restrict access to natural kratom while the clinical evidence base is developing. The January 2026 clinical trial finding kratom safe and well-tolerated has strengthened the position of congressional supporters who advocate for regulation rather than prohibition.

No comprehensive federal kratom legislation has been enacted, but the growing number of KCPA states creates a de facto federal regulatory landscape — vendors operating nationally must comply with the strictest state requirements in their distribution area, which effectively nationalizes KCPA-level standards for the largest vendors. The combination of congressional interest, the FDA-funded safety study, and the DEA's targeted action against 7-OH products rather than natural kratom suggests that the federal regulatory posture toward natural kratom leaf is more stable than at any previous point. Consumers of standard kratom leaf products can purchase with reasonable confidence that federal prohibition is less likely now than it has been at any point in the past decade.

Frequently Asked Questions